The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: MK0767

Inclusion Criteria:

• Men and non-pregnant females
• Age greater than or equal to 21 years
• Stop current diabetes therapy (if applicable)
• Stop current statin therapy (if applicable)

Exclusion Criteria:

• History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
• Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
• Patients requiring treatment with corticosteroids for more than 14 consecutive days
• Patients taking warfarin or warfarin-like anti-coagulants
• Patients undergoing surgery within 30 days of Visit 1
• Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
• Patients with history of pancreatitis or uncontrolled high blood pressure

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 21 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Merck

Overall Clinical Trial Officials and Contacts

Medical Monitor Study Director Merck  

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00547274

Study ID Number: 2007_635

ClinicalTrials.gov Identifier: NCT00547274

Health Authority: United States: Food and Drug Administration